Search

Your search keyword '"Carboplatin -- Intellectual property"' showing total 7 results
Start Over Descriptor "Carboplatin -- Intellectual property" Publisher syndigate media inc.
7 results on '"Carboplatin -- Intellectual property"'

1. Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in combination with a PARP Inhibitor in the United States

Subjects
Carboplatin -- Intellectual property, Cancer -- Care and treatment, DNA damage, Business, international
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO) (hereafter Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response [...]

Published
2021

2. Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA in combination with a PARP Inhibitor in the United States

Subjects
Carboplatin -- Intellectual property, Cancer -- Care and treatment, DNA damage, Business, international, Law
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO) (hereafter Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response [...]

Published
2021

3. Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

Subjects
Carboplatin -- Intellectual property, Immunotherapy, Chemotherapy, Patents, Cancer -- Chemotherapy, Patent/copyright issue, Business, international, Law
Abstract

(GlobeNewswire) - Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant [...]

Published
2021

4. Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA Combined with PARP Inhibitors

Subjects
Cancer treatment, DNA damage, Carboplatin -- Intellectual property, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter Onxeo or the Company, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response [...]

Published
2020

5. Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA Combined with PARP Inhibitors

Subjects
Cancer treatment, DNA damage, Carboplatin -- Intellectual property, Business, international, Law
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter Onxeo or the Company, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response [...]

Published
2020

6. Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA via Systemic Administration in the United States

Subjects
Lung cancer, DNA damage, Chemotherapy, Carboplatin -- Intellectual property, Business, international
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), [...]

Published
2020

7. Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA via Systemic Administration in the United States

Subjects
Lung cancer, DNA damage, Chemotherapy, Carboplatin -- Intellectual property, Business, international, Law
Abstract

(GlobeNewswire) - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (Onxeo or the Company), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results